How the GLP-1 Drug Liraglutide Clears Fat From Liver Cells Through Autophagy and Lipid Metabolism | Research

The takeaway

Liraglutide reversed fatty liver in cell models by activating the AMPK/SIRT1 pathway to both regulate fat metabolism enzymes and enhance autophagy — the cell's self-cleaning process that breaks down accumulated fat.

SIRT1 knockdown abolished liraglutide's liver benefits
When the SIRT1 gene was silenced, liraglutide could no longer induce autophagy or reduce fat accumulation in liver cells — proving this 'longevity pathway' is essential for GLP-1 drugs' liver-protective effects

What the researchers found

Liraglutide significantly reversed free fatty acid-induced hepatocyte steatosis (fatty liver cells) through two complementary mechanisms. First, it regulated lipid metabolism enzymes: decreasing lipogenesis proteins (FAS, ACC1) that make new fat, while increasing lipolysis proteins (ATGL, HSL, LAL) that break down stored fat.

Second, liraglutide enhanced autophagy — the cellular self-digestion process that clears accumulated lipid droplets. Both effects were AMPK-dependent and required SIRT1: when SIRT1 was knocked down, liraglutide could no longer induce autophagy or reduce lipid accumulation. This establishes the AMPK/SIRT1 axis as the critical mediator of GLP-1 receptor agonist activity against hepatic steatosis.

Why it matters

NAFLD affects approximately 25% of people globally and is the fastest-growing indication for liver transplantation. No drug has been specifically approved for NAFLD in most countries, though GLP-1 drugs are increasingly used off-label. This study reveals exactly how liraglutide works against fatty liver at the molecular level — through the AMPK/SIRT1 pathway controlling both fat metabolism and cellular cleanup. Understanding this mechanism could help develop more targeted treatments and identify which NAFLD patients are most likely to respond to GLP-1 therapy.

How the study worked

The study used hepatocyte cell lines (HepG2) treated with free fatty acids to model NAFLD in vitro. Liraglutide was applied to test its effect on fat accumulation. Western blotting measured expression of lipogenesis proteins (FAS, ACC1), lipolysis proteins (ATGL, HSL, LAL), and autophagy markers. SIRT1 knockdown experiments using gene silencing confirmed the pathway dependency. AMPK activation was assessed to establish the signaling cascade.

What this study cannot tell us

The study used HepG2 cell lines, which are hepatocellular carcinoma-derived cells and may not fully represent normal hepatocyte biology. No in vivo animal model was used to confirm the cell culture findings. The AMPK/SIRT1 pathway may not be the only mechanism by which GLP-1 drugs improve NAFLD — weight loss, reduced insulin resistance, and direct hepatic effects through other pathways also contribute. The free fatty acid model of steatosis is simplified compared to the complex pathology of human NAFLD/NASH.

How to read the evidence

This is an in vitro mechanistic study using cell lines with gene knockdown experiments. The molecular pathway evidence is well-constructed with appropriate controls (SIRT1 knockdown), but the findings are limited to cell culture and have not been validated in animal models or human liver tissue.

When this study was published

Published in 2025, this is a very recent study contributing to the rapidly growing understanding of GLP-1 drugs' mechanisms in liver disease.

The bigger picture

GLP-1 receptor agonists are rapidly emerging as treatments for liver disease, complementing their established roles in diabetes and obesity. The SURPASS-6 and SELECT liver outcomes trials have shown clinical benefits. This study adds mechanistic depth by identifying AMPK/SIRT1 as the molecular hub through which GLP-1 drugs act on the liver specifically. SIRT1 — the 'longevity gene' — is also central to caloric restriction benefits, suggesting that GLP-1 drugs may partly mimic the metabolic effects of caloric restriction through this pathway.

Questions still open

Could drugs that directly activate SIRT1 or AMPK provide the same liver fat-clearing benefits as GLP-1 agonists without their gastrointestinal side effects?
Do patients with higher baseline SIRT1 expression respond better to GLP-1 therapy for NAFLD?
Would combining GLP-1 receptor agonists with SIRT1 activators (like resveratrol) produce synergistic effects against fatty liver disease?

Common questions

Can GLP-1 drugs like Ozempic or Victoza treat fatty liver disease?

Growing evidence suggests yes, and this study explains how. Liraglutide (Victoza/Saxenda) was shown to clear fat from liver cells by activating pathways that both reduce fat production and enhance the cell's internal cleanup system (autophagy). Clinical trials of GLP-1 drugs for NAFLD have also shown benefits, though no GLP-1 drug is specifically approved for fatty liver disease yet.

What is autophagy and how does it help with fatty liver?

Autophagy is the cell's self-cleaning process — it digests and recycles damaged or excess cellular components. In fatty liver, autophagy helps break down the accumulated fat droplets inside liver cells (called lipophagy). This study found that liraglutide activates autophagy through the AMPK/SIRT1 pathway, essentially turbocharging the liver's natural fat-clearing mechanism.

Read the original research

GLP-1RAs regulate lipid metabolism and induce autophagy through AMPK/SIRT1 pathway to improve NAFLD.

Prostaglandins & other lipid mediators, 178, 106987

View on PubMed ↗Publisher’s paper ↗

Citation

Zhang, Qiang; Wang, Jingyuan; Hu, Xiaojin; Lu, Wei; Cao, Yang; Niu, Chunyan; Yue, Hongqin. (2025). GLP-1RAs regulate lipid metabolism and induce autophagy through AMPK/SIRT1 pathway to improve NAFLD.. Prostaglandins & other lipid mediators, 178, 106987. https://doi.org/10.1016/j.prostaglandins.2025.106987